Annals of Surgical Oncology

, Volume 24, Issue 2, pp 594–602 | Cite as

Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer

  • Shoichiro Mukai
  • Naohide Oue
  • Takashi Oshima
  • Risa Mukai
  • Yoshiko Tatsumoto
  • Naoya Sakamoto
  • Kazuhiro Sentani
  • Kazuaki Tanabe
  • Hiroyuki Egi
  • Takao Hinoi
  • Hideki Ohdan
  • Wataru Yasui
Translational Research and Biomarkers

Abstract

Background

Gastrointestinal (GI) cancer, including gastric cancer (GC), colorectal cancer (CRC), and esophageal squamous cell carcinoma (ESCC), is the most common malignancy worldwide. To identify genes that encode transmembrane proteins present in GI cancer, Escherichia coli ampicillin secretion trap libraries were generated from MKN-74 GC cells, and BST2 was identified as overexpressed in GC. This study analyzed the expression and function of the BST2 gene in human GI cancers and examined the relationship between bone marrow stromal antigen-2 (BST-2) expression and GI patient clinicopathologic characteristics.

Methods

Expression and distribution of BST-2 protein was analyzed by immunohistochemistry in 180 GC cases, 140 CRC cases, and 132 ESCC cases. Cell growth was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

Results

Immunohistochemical analysis of BST-2 in GC tissues showed that 65 (36 %) of 180 GC cases were positive for BST-2. Uni- and multivariate analyses demonstrated that BST-2 expression is an independent prognostic classifier of GC patients. Immunohistochemical analysis showed that 46 % of 140 CRC cases and 27 % of 132 ESCC cases were positive for BST-2. In ESCC, BST-2 expression was an independent prognostic predictor for survival. The growth of BST2 small interfering RNA (siRNA)-transfected GC cells was significantly slower than the growth of negative control siRNA-transfected GC cells. The levels of phosphorylated epidermal growth factor receptor, extracellular signal-regulated kinase, and Akt were lower in BST2 siRNA-transfected GC cells than in control cells.

Conclusions

The results suggest that BST-2 is involved in tumor progression and serves as an independent prognostic classifier for patients with GC. Because BST-2 is expressed on the cell membrane, BST-2 could be a therapeutic target for GC, CRC, and ESCC.

Supplementary material

10434_2016_5100_MOESM1_ESM.docx (4.7 mb)
Supplementary material 1 (DOCX 4842 kb)

References

  1. 1.
    Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95:385–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015;106:951–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011;23:403–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Ferguson DA, Muenster MR, Zang Q, et al. Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trap. Cancer Res. 2005;65:8209–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Anami K, Oue N, Noguchi T, et al. Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype. J Pathol. 2010;221:275–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Anami K, Oue N, Noguchi T, et al. TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer. Gastric Cancer (in press).Google Scholar
  8. 8.
    Oo HZ, Sentani K, Sakamoto N, et al. Identification of novel transmembrane proteins in scirrhous-type gastric cancer by the Escherichia coli ampicillin secretion trap (CAST) method: TM9SF3 participates in tumor invasion and serves as a prognostic factor. Pathobiology. 2014;81:138–48.CrossRefPubMedGoogle Scholar
  9. 9.
    Oo HZ, Sentani K, Sakamoto N, et al. Overexpression of ZDHHC14 promotes migration and invasion of scirrhous type gastric cancer. Oncol Rep. 2014;32:403–10.PubMedGoogle Scholar
  10. 10.
    Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003;4:694–709.CrossRefPubMedGoogle Scholar
  11. 11.
    Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84:1922–30.PubMedGoogle Scholar
  12. 12.
    Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood. 1997;90:3179–86.PubMedGoogle Scholar
  13. 13.
    Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 2003;63:8939–47.PubMedGoogle Scholar
  14. 14.
    Cai D, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009;9:102.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yokoyama T, Enomoto T, Serada S, et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer. 2013;132:472–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang W, Nishioka Y, Ozaki S, et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother. 2009;58:967–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002, pp 65–8.Google Scholar
  18. 18.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  19. 19.
    Oue N, Noguchi T, Anami K, et al. Cytokeratin 7 is a predictive marker for survival in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:1902–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson AH, Frierson HF, Zaika A, et al. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol. 2005;167:577–84.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Sayeed A, Luciani-Torres G, Meng Z, Bennington JL, Moore DH, Dairkee SH. Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One. 2013;8:e67191.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 2005;4:151–68.PubMedGoogle Scholar
  24. 24.
    Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA’ induces apoptosis in multiple myeloma cells. Blood Cancer J. 2014;4:e219.Google Scholar
  25. 25.
    Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010;277:316–26.CrossRefPubMedGoogle Scholar
  26. 26.
    Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed Res Int. 2014;2014:965384.Google Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Shoichiro Mukai
    • 1
    • 2
  • Naohide Oue
    • 1
  • Takashi Oshima
    • 3
  • Risa Mukai
    • 1
  • Yoshiko Tatsumoto
    • 1
  • Naoya Sakamoto
    • 1
  • Kazuhiro Sentani
    • 1
  • Kazuaki Tanabe
    • 2
  • Hiroyuki Egi
    • 2
  • Takao Hinoi
    • 2
  • Hideki Ohdan
    • 2
  • Wataru Yasui
    • 1
  1. 1.Department of Molecular PathologyHiroshima University Graduate School of Biomedical SciencesHiroshimaJapan
  2. 2.Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health SciencesHiroshima UniversityHiroshimaJapan
  3. 3.Department of SurgeryYokohama City UniversityYokohamaJapan

Personalised recommendations